US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INVESCO BIOTECHNOLOGY & GENOME ETF

95.07

-0.0300-0.03%

Post-market: 95.070.00000.00%19:30 EDT

Volume:18.13K

Turnover:1.72M

Market Cap:412.60M

PE:53.01

High:95.58

Open:95.58

Low:94.62

Close:95.10

52wk High:98.82

52wk Low:70.01

Shares:4.34M

Float Shares:4.34M

Volume Ratio:1.42

T/O Rate:0.42%

Dividend:1.33

Dividend Rate:1.40%

EPS(TTM):1.79

EPS(LYR):18.65

ROE:24.76%

ROA:0.08%

PB:1.67

PE(LYR):5.10

Loading ...

Overview Company News Filings

Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease

THOMSON REUTERS

Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity

THOMSON REUTERS

Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026

THOMSON REUTERS

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)

Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Analysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA) and Alnylam Pharma (ALNY)

Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594

THOMSON REUTERS

Sino Biopharmaceutical Stock Rises 8.2% in Hong Kong, Outperforms Competitors

Innovative Drug Sector Heats Up: Spotlight on Pure-Play R&D Developers

Correction to Vertex Material Listing Article on Sept. 17

Amgen Inc. Stock Outperforms Competitors on Strong Trading Day

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/PBE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PBE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBE\",,,,,undefined,":{"symbol":"PBE","market":"US","secType":"STK","nameCN":"INVESCO BIOTECHNOLOGY & GENOME ETF","latestPrice":95.07,"timestamp":1790971200000,"preClose":95.1,"halted":0,"volume":18134,"hourTrading":{"tag":"盘后","latestPrice":95.07,"preClose":95.07,"latestTime":"19:30 EDT","volume":13,"amount":1236.27,"timestamp":1790983804616,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0003154574132492233,"floatShares":4340000,"shares":4340000,"eps":1.793292,"marketStatus":"Market Closed","change":-0.03,"latestTime":"10-02 16:00:00 EDT","open":95.58,"high":95.58,"low":94.6201,"amount":1723082.16228,"amplitude":0.010094,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":1.793292,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":95.1,"sharesOutstanding":3180000,"nav":95.03449,"aum":415735297.01,"dividendRate":0.014012,"bidAskSpread":0.002055,"postHourTrading":{"tag":"盘后","latestPrice":95.07,"preClose":95.07,"latestTime":"19:30 EDT","volume":13,"amount":1236.27,"timestamp":1790983804616,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.4172945469476637,"impliedVol":0.1398,"impliedVolPercentile":0.0677},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBE\",,,,,undefined,":{"symbol":"PBE","floatShares":4340000,"roa":"0.08%","roe":"24.76%","lyrEps":18.654418,"volumeRatio":1.4172945469476637,"shares":4340000,"dividePrice":1.3321,"high":95.58,"amplitude":0.010094,"preClose":95.1,"low":94.6201,"week52Low":70.01,"pbRate":"1.67","psRate":"240.35","week52High":98.82,"institutionHeld":0.2552,"latestPrice":95.07,"eps":1.793292,"divideRate":0.014012,"volume":18134,"delay":0,"ttmEps":1.793292,"open":95.58,"prevYearClose":82.15,"prevWeekClose":97.26,"prevMonthClose":97.2888,"prevQuarterClose":97.2888,"fiveDayClose":97.26,"twentyDayClose":98.7191,"sixtyDayClose":93.0146},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBE\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"PBE","amount":0.01867,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-25"},{"date":"2026-06-22","symbol":"PBE","amount":0.81061,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"PBE","amount":0.08244,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"PBE","amount":0.41972,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"PBE","amount":0.23409,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBE\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.1208,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-31","value":0.05552,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-30","value":0.21532,"currency":"USD"},{"executeDate":"2018-09-24","recordDate":"2018-09-25","paymentDate":"2018-09-28","value":0.00207,"currency":"USD"},{"executeDate":"2020-03-23","recordDate":"2020-03-24","paymentDate":"2020-03-31","value":0.02898,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669414223","title":"Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414223","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414223?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:04","pubTimestamp":1790082271,"startTime":"0","endTime":"0","summary":"Amgen says Phase 3 trial shows dazodalibep cuts systemic disease activity in Sjgren’s diseaseAmgen reported positive topline Phase 3 results for dazodalibep in adults with moderate-to-severe systemic ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL63L4Jz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU0889565916.HKD","IE0009355771.USD","LU0109394709.USD","BK4581","TBXU","LU1983299246.USD","PJP","LU1023059063.AUD","LU2468319806.SGD","BK4534","LU2242652126.USD","LU0320765992.SGD","LU0868494617.USD","LU0058720904.USD","IBBQ","LU0289739699.SGD","IE00B2B36J28.USD","PBE","IE00BJJMRZ35.SGD","IE0002141913.USD","LU1057294990.SGD","BK4139","BK4566","LU2242646821.SGD","SG9999001440.SGD","LU1571399168.USD","BK4585","BIB","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1061106388.HKD","IBB","LU2112291526.USD","BBH","IE00BJT1NW94.SGD","BK4599","BK4588","BK4533","LU2089984988.USD","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142464","title":"Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142464?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082154,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated::*VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSD66vtCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0079474960.USD","LU2362540622.SGD","IBB","BK4533","PBE","LU1674673691.USD","IE00BFTCPJ56.SGD","LU0234570918.USD","LU0823416689.USD","LU0289739699.SGD","LU2237438978.USD","VRTX","LU2468319806.SGD","BK4532","BK4567","LU2362541513.USD","GNMX","LU1093756168.USD","LU2089984988.USD","LU0432979614.USD","LU1035775433.USD","IE00B2B36J28.USD","LU2236285917.USD","LU0256863811.USD","BK4585","IE0002141913.USD","BK4139","IE00B4R5TH58.HKD","IE0009355771.USD","LU0320765992.SGD","IDNA","IE00B894F039.SGD","LU0417517546.SGD","LU2362541273.HKD","LU0889565916.HKD","BIB","IE00BJT1NW94.SGD","BBH","BK4588","IE00B19Z3B42.SGD","IE00B19Z9P08.USD","SG9999001176.SGD","LU0061475181.USD","TBXU","SG9999013999.USD","LU1093756325.SGD","IBBQ","LU2417539215.USD","IE00B19Z9Z06.USD","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142967","title":"Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142967?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082029,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E0FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","PJP","BBH","BIB","BK4534","LU2468319806.SGD","BK4581","LU1571399168.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4599","BK4588","LU0320765992.SGD","BK4585","IE0002141913.USD","LU0109394709.USD","LU2242646821.SGD","LU0868494617.USD","IE0009355771.USD","LU1023059063.AUD","AMGN","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1057294990.SGD","LU0058720904.USD","LU0122379950.USD","LU1061106388.HKD","LU1983299246.USD","BK4533","LU0289739699.SGD","IBBQ","PBE","BK4139","BK4566","LU2242652126.USD","LU2112291526.USD","SG9999001440.SGD","TBXU","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142945","title":"Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142945?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","PJP","BBH","BIB","BK4534","LU2468319806.SGD","BK4581","LU1571399168.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4599","BK4588","LU0320765992.SGD","BK4585","IE0002141913.USD","LU0109394709.USD","LU2242646821.SGD","LU0868494617.USD","IE0009355771.USD","LU1023059063.AUD","AMGN","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1057294990.SGD","LU0058720904.USD","LU0122379950.USD","LU1061106388.HKD","LU1983299246.USD","BK4533","LU0289739699.SGD","IBBQ","PBE","BK4139","BK4566","LU2242652126.USD","LU2112291526.USD","SG9999001440.SGD","TBXU","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142617","title":"Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142617?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1057294990.SGD","BK4534","IE00BJJMRZ35.SGD","BBH","PBE","LU0320765992.SGD","BK4599","LU0122379950.USD","LU0889565916.HKD","LU0868494617.USD","BK4585","BIB","LU1983299246.USD","BK4581","SG9999001440.SGD","IE0009355771.USD","IE0002141913.USD","LU0058720904.USD","IBB","AMGN","IE00B2B36J28.USD","IBBQ","LU2112291526.USD","LU1023059063.AUD","IE00B4R5TH58.HKD","BK4588","IE00BFTCPJ56.SGD","BK4566","LU0289739699.SGD","IE00BJT1NW94.SGD","PJP","LU2242646821.SGD","LU2242652126.USD","LU1061106388.HKD","LU2089984988.USD","LU2468319806.SGD","BK4533","TBXU","LU0109394709.USD","LU1571399168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669425861","title":"Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669425861","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669425861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:50","pubTimestamp":1790081406,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","IE00BZ9MQY76.HKD","IE0009355771.USD","SG9999001176.USD","LU1674673428.USD","IE00B19Z9P08.USD","LU0757428866.USD","IE00B19Z3581.USD","LU2236285917.USD","LU2468319806.SGD","BK4532","LU2089984988.USD","BBH","BK4139","BK4567","LU1559883803.SGD","LU1778281490.HKD","BK4023","TBXU","LU0061475181.USD","IE0002141913.USD","SGXZ57979304.SGD","SG9999013999.USD","IDNA","LU2417539215.USD","IE00BJJMRZ35.SGD","GNMX","PBE","IE0002270589.USD","LU1069344957.HKD","IE00BJT1NW94.SGD","LU1093756325.SGD","BK4533","LU2324357040.USD","LU0566484027.USD","LU2362540622.SGD","LU1035775433.USD","IE00B894F039.SGD","LU0058720904.USD","IBBQ","SG9999001176.SGD","VRTX","IE00B19Z9Z06.USD","LU1674673691.USD","BIB","LU0079474960.USD","BK4588","VERX","LU2362541513.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144313","title":"Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144313","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144313?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:15","pubTimestamp":1790079331,"startTime":"0","endTime":"0","summary":"The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","LU1430594728.SGD","IE00B19Z3B42.SGD","LU0061475181.USD","LU1585245621.USD","IE00B19Z9Z06.USD","IBBQ","IE0009355771.USD","LU2089984988.USD","LU2237438978.USD","BIB","IE00BJT1NW94.SGD","SG9999013999.USD","LU0432979614.USD","VERX","LU1093756325.SGD","LU0234570918.USD","LU2462157665.USD","IE00B19Z9P08.USD","LU1674673428.USD","LU1815336091.USD","IE0002141913.USD","BK4532","GNMX","LU1778281490.HKD","IE00B4R5TH58.HKD","LU0289739699.SGD","BBH","IE00B2B36J28.USD","LU1035775433.USD","TBXU","IBB","IE00B19Z3581.USD","LU0109394709.USD","SG9999001176.SGD","BK4139","LU0757428866.USD","LU0823416689.USD","LU2236285917.USD","BK4567","BK4023","LU1674673691.USD","BK4588","IDNA","LU1093756168.USD","LU2362540622.SGD","PBE","VRTX","LU0320765992.SGD","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177141","title":"Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:02","pubTimestamp":1790078577,"startTime":"0","endTime":"0","summary":"Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuriaVertex reported positive Phase 2b AMPLIFIED results for inaxaplin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL8CHhBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","IE00B19Z9P08.USD","BK4139","IBBQ","LU1093756168.USD","BK4567","IBB","IDNA","IE00BJT1NW94.SGD","SG9999001176.SGD","BIB","LU2462157665.USD","IE00BFTCPJ56.SGD","IE0002270589.USD","LU1069344957.HKD","LU2362541273.HKD","BBH","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1674673691.USD","LU0320765992.SGD","LU0061475181.USD","LU2468319806.SGD","LU1093756325.SGD","SG9999013999.USD","LU0256863811.USD","LU0058720904.USD","BK4585","LU2324357040.USD","LU0432979614.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","LU0079474960.USD","LU2362541513.USD","VRTX","IE0002141913.USD","BK4532","IE0009355771.USD","IE00BZ9MQY76.HKD","LU1035775433.USD","LU2237438978.USD","TBXU","LU1674673428.USD","BK4588","LU0823416689.USD","LU0109394709.USD","IE00B2B36J28.USD","IE00B19Z9Z06.USD","GNMX","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419861","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","VRTX","BBH","IBBQ","IE00B2B36J28.USD","PBE","BK4139","IE00BJJMRZ35.SGD","LU0256863811.USD","IE00B19Z3581.USD","LU1674673691.USD","LU2417539215.USD","LU2456880835.USD","IBB","LU1069344957.HKD","LU2236285917.USD","LU2462157665.USD","LU1778281490.HKD","TBXU","IE0002141913.USD","IE0002270589.USD","BK4585","LU0889565916.HKD","LU2362541513.USD","SG9999001176.SGD","SGXZ57979304.SGD","LU2362541273.HKD","IE0009355771.USD","BIB","LU1585245621.USD","LU0823416689.USD","LU2237438978.USD","LU0234570918.USD","GNMX","LU1674673428.USD","IE00B19Z9P08.USD","LU1093756168.USD","IE00B894F039.SGD","LU0289739699.SGD","LU1430594728.SGD","LU0079474960.USD","LU0417517546.SGD","LU2362540622.SGD","LU2468319806.SGD","IE00B4R5TH58.HKD","LU2324357040.USD","IDNA","IE00BJT1NW94.SGD","LU1093756325.SGD","IE00B19Z9Z06.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419041","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419041?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0061475181.USD","LU0058720904.USD","LU1585245621.USD","IE00B19Z9Z06.USD","LU2456880835.USD","BK4533","IBBQ","LU2089984988.USD","LU2237438978.USD","IE00BJT1NW94.SGD","BIB","SG9999013999.USD","LU0432979614.USD","LU2362541273.HKD","LU1093756325.SGD","LU0234570918.USD","LU2462157665.USD","IE00B19Z9P08.USD","LU1674673428.USD","LU2324357040.USD","BK4585","IE00BZ9MQY76.HKD","IE0002141913.USD","BK4532","LU1069344957.HKD","GNMX","LU1778281490.HKD","IE00B4R5TH58.HKD","BBH","LU1035775433.USD","TBXU","IBB","LU0109394709.USD","IE0002270589.USD","LU0889565916.HKD","SG9999001176.SGD","SGXZ57979304.SGD","BK4139","LU2417539215.USD","BK4567","BK4588","IDNA","SG9999001176.USD","LU2362541513.USD","PBE","IE00BJJMRZ35.SGD","VRTX","LU0320765992.SGD","LU0256863811.USD","LU0079474960.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141954","title":"Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141954?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU2237438978.USD","LU0823416689.USD","IE00B19Z9P08.USD","LU1035775433.USD","LU0109394709.USD","LU1069344957.HKD","LU1093756325.SGD","BK4532","SG9999013999.USD","BIB","IDNA","IE00BZ9MQY76.HKD","LU2236285917.USD","IE00B4R5TH58.HKD","LU0256863811.USD","IE00B19Z3581.USD","BK4585","LU1778281490.HKD","LU1674673691.USD","LU0079474960.USD","IBB","IE0002141913.USD","IE00B2B36J28.USD","PBE","LU1585245621.USD","BK4533","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1674673428.USD","LU2456880835.USD","SG9999001176.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4567","SGXZ57979304.SGD","VRTX","IBBQ","LU0058720904.USD","LU0320765992.SGD","LU0432979614.USD","GNMX","TBXU","BK4139","LU0234570918.USD","LU2089984988.USD","BBH","LU0061475181.USD","LU0417517546.SGD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143096","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143096?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:10","pubTimestamp":1790071809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA). ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","LU0868494617.USD","LU0058720904.USD","LU0109394709.USD","BK4139","IE00B2B36J28.USD","BK4585","LU1057294990.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","BK4599","LU1983299246.USD","AMGN","SG9999001440.SGD","BK4588","IE0002141913.USD","LU1061106388.HKD","LU2468319806.SGD","TBXU","LU0029874061.USD","BK4533","HCSG","LU1023059063.AUD","LABU","BK4539","IVVD","LU2089984988.USD","PJP","BIB","IBB","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU2242646821.SGD","LU0122379950.USD","LU1571399168.USD","BK4137","BK4566","IBBQ","LU0128526141.USD","IE0009355771.USD","LU0289739699.SGD","BK4563","XLV","XBI","LU0889565916.HKD","PBE","LU2242652126.USD","IE00BJJMRZ35.SGD","BBH","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669511784","title":"Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669511784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669511784?lang=en_us&edition=fundamental","pubTime":"2026-09-22 16:32","pubTimestamp":1790065920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. slipped 1.4% to 5.84 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 25087.75.Sino Biopharmaceutical Ltd. closed 32% short of its 52-week high of HK$8.56, which the company reached Sept. 23.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 1.1% and Amgen Inc. remained unchanged.Trading volume totaled 87.2 million shares, compared to the 50-day average of 88.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","PBE","LU2089984988.USD","LU2242646821.SGD","IE00B2B36J28.USD","LU0122379950.USD","BK4139","IE00B4R5TH58.HKD","LU0320765992.SGD","BK1589","BIB","IE00BZ08YR35.GBP","LU2468319806.SGD","BK4534","IBB","BK4588","LU0058720904.USD","IE0002141913.USD","LU0289739699.SGD","LU1023059063.AUD","LU1061106388.HKD","LU1571399168.USD","BK4566","IE00BFTCPJ56.SGD","LU1057294990.SGD","BBH","BK1515","IE00BZ08YS42.EUR","IE00BJJMRZ35.SGD","BK4581","PJP","LU2112291526.USD","IE0009355771.USD","BK4585","LU0109394709.USD","IE00BZ08YT58.USD","AMGN","LU0889565916.HKD","BK4533","TBXU","BK4599","SG9999001440.SGD","LU1983299246.USD","HK0000165453.HKD","LU2242652126.USD","BK1521","IBBQ","LU0868494617.USD","IE00BJT1NW94.SGD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669193999","title":"Biogen Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2669193999","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669193999?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:56","pubTimestamp":1790024160,"startTime":"0","endTime":"0","summary":"DJ Biogen Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Biogen Inc.  rose 1.66% to $219.07 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 1.49% to 7,764.70 and the Dow Jones Industrial Average  rising 0.71% to 52,048.83.Biogen Inc. closed 2.98% short of its 52-week high of $225.80, which the company achieved on September 3rd.The stock outperformed some of its competitors Monday, as Johnson & Johnson  fell 0.19% to $269.47, Pfizer Inc.  rose 0.29% to $27.74, and AbbVie Inc.  rose 0.20% to $264.48.Trading volume  remained 96,480 below its 50-day average volume of 1.0 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 21, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B1BXHZ80.USD","LU0098860793.USD","LU0345769128.USD","LU1145028129.USD","SG9999015952.SGD","LU0234572021.USD","LU0726765562.USD","LU2468319806.SGD","LU1496350171.SGD","LU2112291526.USD","LU0792757196.USD","LU0210528500.USD","PBE","LU2750360997.AUD","LU0310800379.SGD","LU0965509101.SGD","LU1629891620.HKD","PJP","LU2357627491.SGD","LU2471134879.HKD","LU0965509283.SGD","LU0912757837.SGD","LU1914381329.SGD","LU1261432733.SGD","LU0661504455.SGD","LU2471134523.USD","LU2089284900.SGD","IE00BJT1NW94.SGD","LU2487616109.SGD","LU0289961442.SGD","OZEM","LU1674673691.USD","LU2596442595.SGD","IE0009355771.USD","LU1267930573.SGD","LU1037948541.HKD","LU2505996681.GBP","LU0124676726.USD","LU2756315318.SGD","LU2430703095.HKD","LU1236620834.HKD","BK4504","IE00BSNM7G36.USD","LU0203345920.USD","LU0472753341.HKD","LU0820562030.AUD","LU0795875086.SGD","IE00BVYPNV92.GBP","IE00B894F039.SGD","LU1043141123.HKD","LU1280957306.USD","LU1037948897.HKD","LU1551013425.SGD","LU0417517546.SGD","LU0511384066.AUD","LU1720051017.SGD","LU1236620750.USD","LU1032955483.USD","LU1066051498.USD","LU1196500208.SGD","LU2129689431.USD","LU0072461881.USD","IE00BKVL7J92.USD","JDOC","LU0321505868.SGD","LU0158827948.USD","LU0965509010.AUD","LU1162221912.USD","LU0964807845.USD","LU2087621335.USD","MEDX","BK4532","IE00BBT3K403.USD","LU1221951046.USD","SG9999002224.SGD","IE000F7OJYX1.SGD","LU1093756325.SGD","BK4599","SG9999015978.USD","LU0943347566.SGD","LU1935042991.SGD","LU0426412945.USD","LU2456880835.USD","SG9999001440.SGD","LU0738911758.USD","LU2023250330.USD","LU0868494708.USD","IE0034235303.USD","LU0029864427.USD","LU0553294199.USD","LU1496350502.SGD","LU1506573853.SGD","LU1551013342.USD","LU0170899867.USD","LU1839511570.USD","LU0882574055.USD","LU1983299246.USD","LU0256863902.USD","IE000M9KFDE8.USD","LU1585245621.USD","RXL","LU2133065610.SGD","IE00B3T34201.USD","IE00B19Z9P08.USD","LU0545562505.USD","LU1244550577.SGD","LU1430594728.SGD","LU0128525929.USD","LU1043141396.HKD","LU2505996509.AUD","LU2433249047.HKD","IE00B7SZLL34.SGD","LU0289739343.SGD","LU2602419157.SGD","LU1989771016.USD","LU1989772923.USD","LU0823416689.USD","IE00B2B36J28.USD","LU1074936037.SGD","LU1883839398.USD","LU2756315664.SGD","BK4568","IE00B4R5TH58.HKD","SGXZ80539844.SGD","ABBV","LU2129689605.HKD","IYH","LU1059921491.USD","SGXZ57979304.SGD","LU0306806265.USD","LU1718418525.SGD","LU1778281490.HKD","LU0456855351.SGD","LU0122379950.USD","LU0320765992.SGD","LU0861579265.USD","BK4534","BMED","IE00BVYPNW00.USD","LU2417539215.USD","LU0289739699.SGD","IE000WAW04H5.SGD","IE00B3PB1722.GBP","IE000MB6IJN5.SGD","LU1267930490.SGD","LU0985481810.HKD","LU1221951129.SGD","LU2357305700.SGD","GLAM","LU0225771236.USD","IHE","LU0198837287.USD","LU0069063385.USD","LU1066051225.USD","XLV","SG9999001176.SGD","LU0211328371.USD","LU2750360641.GBP","TRUH","LU0109394709.USD","LU1894683348.USD","IE00B19Z3B42.SGD","LU1228905037.USD","SG9999015945.SGD","LU1934455194.USD","VHT","LU0545039389.USD","LU0306807586.USD","LU1267930813.SGD","IE00BLSP4452.SGD","SG9999011175.SGD","BK4550","IE00BZ1G4Q59.USD","IE00BLSP4239.USD","LU0345769631.USD","LU0256863811.USD","LU0395794307.EUR","BK4585","LU1023059063.AUD","LU1244550221.USD","AGNG","IE00BDGV0183.EUR","LU1732799900.SGD","BK4139","LU0820561818.USD","LU1732800096.USD","LU2129689514.USD","LU2237443622.USD","LU1923622614.USD","LU0889565916.HKD","LU1244550494.USD","LU0708994859.HKD","LU0210536198.USD","LU0321505439.SGD","JNJ","LU0426417589.USD","LU1057294990.SGD","LU2236285917.USD","PPH","LU1093756168.USD","IE0002141913.USD","SG9999003800.SGD","LU0683600562.USD","LU0203347892.USD","IE00B19Z3581.USD","LU2237443465.HKD","LU0211327993.USD","LU0994945656.USD","LU2896262040.SGD","LU0114720955.EUR","LU1548497426.USD","LU2237443549.SGD","LU2237443978.SGD","LU2237443382.USD","LU1061106388.HKD","LU2347655156.SGD","LU0820561909.HKD","LU0057025933.USD","LU1670628061.USD","BK4533","LU2213496289.HKD","IE000SO60NU8.SGD","LU1934455277.USD","BIIB","SG9999015986.USD","IE00BGHQF631.EUR","LU0965508806.USD","LU0432979614.USD","LU1066053197.SGD","IE00BJJMRZ35.SGD","LU1032466523.USD","LU0868494617.USD","SG9999013999.USD","LU0058720904.USD","LU0942090050.USD","LU1066051811.HKD","LU1291159041.SGD","PFE","LU0787776722.HKD","GDOC","IE00BFTCPJ56.SGD","LU1934455863.HKD","SG9999001176.USD","LU1989772840.SGD","IE00B42XCP33.USD","IE000BZT7R73.USD","LU0949170772.SGD","LU1003077747.HKD","LU2471134796.USD","LU2125909593.SGD","FTXH","LU0795875169.SGD","LU2430703251.USD","LU0689626769.HKD","LU0070217475.USD","LU2023251221.USD","IE0004445239.USD","LU0985320562.USD","LU2347655073.USD","IE00BFXG1179.USD","IXJ","IE00B19Z9Z06.USD","LU0162691827.USD","LU1121112475.USD","LU0889566641.SGD","LU1720051108.HKD","LU2237443895.HKD","BK4007","LU0320765646.SGD","LU2592432038.USD","LU2430703178.SGD","BK4559","IE0001KFT4U8.USD","LU1228905540.USD","LU0345770993.USD","LU0689472784.USD","BK4581","SG9999002232.USD","LU0466842654.USD","BK4588","LU0053666078.USD","LU2089283258.USD","BK4592","LU0640476718.USD","LU0345770308.USD","LU1674673428.USD","LU2089984988.USD","IE0002270589.USD","LU2471134952.CNY","IE0000B7K699.USD","LU0234570918.USD","IE00BN8TJ469.HKD","LU2403377893.USD","LU0859254822.USD","LU1929549753.HKD","LU2125909247.SGD","LU0310799852.SGD","LU1894683264.USD","LU0225284248.USD","LU1670627923.USD","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150936","title":"Analysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA) and Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150936","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150936?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:40","pubTimestamp":1789987218,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Innate Pharma (IPHA) and Alnylam Pharma (ALNY) with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-innate-pharma-ipha-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-innate-pharma-ipha-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","LU0109394709.USD","IPHA","ALNY","LU0320765992.SGD","BK4581","LU0889565916.HKD","BK4137","PBE","BK4585","BK4139","LU0882574055.USD","HCSG","LU0128526141.USD","XLV","LU0114720955.EUR","XBI","BK4588","GNMX","BK4548","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669315293","title":"Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594","url":"https://stock-news.laohu8.com/highlight/detail?id=2669315293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669315293?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:03","pubTimestamp":1789985027,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009355771.USD","LU2456880835.USD","LU0109394709.USD","LU0061475181.USD","LU2362540622.SGD","LU2462157665.USD","TBXU","BK4567","LU2468319806.SGD","LU1093756325.SGD","LU0320765992.SGD","LU2236285917.USD","LU0058720904.USD","LU2362541273.HKD","LU1093756168.USD","IBBQ","LU1585245621.USD","LU0289739699.SGD","IDNA","PBE","IE00BJJMRZ35.SGD","GNMX","LU0823416689.USD","IE00BZ9MQY76.HKD","BK4139","LU1674673428.USD","LU2324357040.USD","LU2362541513.USD","BIB","LU0234570918.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","BK4532","IE00B894F039.SGD","IE00BFTCPJ56.SGD","LU1035775433.USD","IBB","SG9999001176.SGD","BBH","IE00BJT1NW94.SGD","LU0256863811.USD","BK4588","LU1069344957.HKD","LU2417539215.USD","VRTX","LU1778281490.HKD","BK4533","LU2089984988.USD","SG9999013999.USD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156720","title":"Sino Biopharmaceutical Stock Rises 8.2% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156720","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669156720?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:30","pubTimestamp":1789979400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. rallied 8.2% to 5.92 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.2% to 25042.71.Sino Biopharmaceutical Ltd. closed 32% below its 52-week high of HK$8.65, which the company achieved Sept. 22.The stock outperformed some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 7.6% and Amgen Inc. remained unchanged.Trading volume totaled 150.2 million shares, compared to the 50-day average of 89.1 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PJP","IBB","IE0009355771.USD","LU2242646821.SGD","LU0889565916.HKD","IE00B2B36J28.USD","LU0109394709.USD","LU2468319806.SGD","LU2089984988.USD","AMGN","LU1057294990.SGD","LU1571399168.USD","BBH","BK4139","LU1983299246.USD","LU0868494617.USD","TBXU","BK4581","HK0000165453.HKD","IE0002141913.USD","BK1191","IE00BZ08YT58.USD","LU2112291526.USD","LU2242652126.USD","BK4534","SG9999001440.SGD","BK4599","BK1589","IE00BZ08YR35.GBP","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00BZ08YS42.EUR","PBE","IE00BJT1NW94.SGD","BK4566","BK4533","LU1023059063.AUD","01177","LU0058720904.USD","IBBQ","LU0122379950.USD","BK1521","BIB","BK1515","BK4588","IE00B4R5TH58.HKD","LU0289739699.SGD","LU0320765992.SGD","LU1061106388.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181721651","title":"Innovative Drug Sector Heats Up: Spotlight on Pure-Play R&D Developers","url":"https://stock-news.laohu8.com/highlight/detail?id=1181721651","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181721651?lang=en_us&edition=fundamental","pubTime":"2026-09-21 14:01","pubTimestamp":1789970464,"startTime":"0","endTime":"0","summary":"A bullish MACD crossover signal has emerged, indicating strong upward momentum for select pharmaceutical stocks. This technical indicator, often seen as a precursor to sustained gains, has caught the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","SBIO","GDOC","BK4585","BK4588","BK1161","BBP","LFSC","MEDX","GSKH","APXH","IBBQ","BK1574","159992","BIOY","06978","XLVI","LNGR","IBB","WRND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669412132","title":"Correction to Vertex Material Listing Article on Sept. 17","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412132","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412132?lang=en_us&edition=fundamental","pubTime":"2026-09-21 12:48","pubTimestamp":1789966080,"startTime":"0","endTime":"0","summary":"Tan Chin Teong is the founder and technical director of Vertex Material. \"Malaysia's Vertex Material Sets Sights on 2027 U.S. Listing,\" at 0931 GMT on Sept. 17, misstated the name as Tan Chin Tong.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU0823416689.USD","IE00B19Z9Z06.USD","SGXZ57979304.SGD","IDNA","LU0889565916.HKD","TBXU","BK4588","LU2362541513.USD","LU1035775433.USD","LU2462157665.USD","LU0079474960.USD","LU0256863811.USD","LU1778281490.HKD","VRTX","LU1093756168.USD","PBE","IE00B19Z3B42.SGD","BK4567","LU2324357040.USD","SG9999001176.USD","SG9999013999.USD","IE00B19Z9P08.USD","LU0417517546.SGD","LU0566484027.USD","IE00BFTCPJ56.SGD","LU2236285917.USD","SG9999001176.SGD","LU2362540622.SGD","LU0234570918.USD","LU1585245621.USD","IBB","LU2089984988.USD","BIB","LU0058720904.USD","LU1069344957.HKD","GNMX","LU0320765992.SGD","IBBQ","BK4023","VERX","LU2468319806.SGD","LU2362541273.HKD","LU0109394709.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU1093756325.SGD","IE00BJJMRZ35.SGD","IE00B894F039.SGD","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973164","title":"Amgen Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973164","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973164?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:34","pubTimestamp":1789763640,"startTime":"0","endTime":"0","summary":"DJ Amgen Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Amgen Inc.  rallied 1.55% to $385.65 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  rising 0.17% to 7,650.50 and the Dow Jones Industrial Average  falling 0.18% to 51,682.64.This was the stock's third consecutive day of gains.Amgen Inc. closed 13.73% below its 52-week high of $447.03, which the company reached on August 25th.The stock outperformed some of its competitors Friday, as Johnson & Johnson  fell 0.09% to $269.99, Pfizer Inc.  rose 0.07% to $27.66, and AbbVie Inc.  fell 0.02% to $263.96.Trading volume  eclipsed its 50-day average volume of 2.6 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 18, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","BBH","LU0109394709.USD","LU0868494617.USD","BK4566","LU1057294990.SGD","LU0122379950.USD","LU0889565916.HKD","BK4599","BK4534","LU2112291526.USD","BK4588","IE0002141913.USD","IE00BJJMRZ35.SGD","PJP","PBE","IBB","SG9999001440.SGD","BK4585","LU1983299246.USD","04332","BK4139","BK4533","TBXU","IBBQ","LU0289739699.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","AMGN","LU1571399168.USD","BK4581","LU2468319806.SGD","LU0320765992.SGD","LU1023059063.AUD","BIB","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}